Plain-English translation of NCT07106021 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which involves surgically implanting dopamine-producing stem cells directly into a specific area of the brain called the putamen. Researchers want to see if this treatment is safe and whether it can help reduce Parkinson's symptoms. The study will enroll 12 patients and test different doses to find the safest and most effective amount.
Current Parkinson's medications work well for some people but lose effectiveness over time, and they don't replace the brain cells that are damaged by the disease. This medication aims to address the root cause by directly replacing those lost cells, potentially offering a longer-lasting benefit.
If you join this study, you would undergo a surgical procedure to have cells implanted into your brain. The study tests three different dose levels, with early participants receiving lower doses and later participants potentially receiving higher doses based on safety data. You would be closely monitored after surgery with regular visits to assess both safety and whether your Parkinson's symptoms improve.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States